Reliance Securities
Cadila Healthcare (Buy)
CMP: ₹363.9
Target: ₹450
Cadila Healthcare is an Indian pharmaceutical company headquartered at Ahmedabad in Gujarat State of western India. The company is the fourth largest pharmaceutical company in India, with ₹5,470-crore revenue. It is a significant manufacturer of generic drugs.
Cadila Healthcare (CDH) is one of the largest domestic pharma companies in India with a strong focus on niche segment in the
US market.
We believe that CDH’s long-term fundamentals continue to remain intact on the back of rich pending product pipeline (including high-value products in the US). Looking ahead, we expect CDH’s US business to clock 10 per cent CAGR over FY18-20E led by new launches (50+ products in FY19E).
We expect CDH’s domestic business to clock 14 per cent CAGR over FY18-20E led by new launches. It launched 64 new roducts in FY18.
We expect CDH’s sales and net profit to clock 12 per cent CAGR through FY18-20E.
We maintain our ‘buy’ recommendation on the stock with a target price of ₹450, valuing the stock at 20x FY20E EPS of ₹22.5.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.